Previous 10 | Next 10 |
Marinus Pharmaceuticals, Inc. (MRNS) Q3 2020 Earnings Conference Call November 09, 2020 04:30 PM ET Company Participants Sasha Damouni Ellis - VP, IR and Corporate Communications Scott Braunstein - CEO Joe Hulihan - CMO Edward Smith - VP and CFO Conference Call Participants Joseph Thome - Cow...
Marinus Pharmaceuticals (MRNS): Q3 GAAP EPS of -$0.51 beats by $0.09.Revenue of $0.17M misses by $0.21M.Press Release For further details see: Marinus Pharmaceuticals EPS beats by $0.09, misses on revenue
Reported positive topline data from pivotal Phase 3 Marigold Study of oral ganaxolone in children and young adults with CDKL5 deficiency disorder (CDD) Awarded five-year cost-sharing contract with Biomedical Advanced Research and Development Authority (BARDA), part of the Office o...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that Christy Shafer has been appointed Chief Commercial Officer, reporting to Scott Braunstein, M.D., Chief...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it will release financial results for the third quarter ended September 30, 2020 after the market clos...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that company management will participate in a Truist Virtual Fireside Chat, the Guggenheim Virtual Conferen...
Truist initiates Marinus Pharmaceuticals ([[MRNS]] +7.4%) at Buy, PT $35 (indicating more than double increase from current levels); in past 6-months trading, stock has gained 60%.Wall Street Analysts rating is Very Bullish.Analyst Joon Lee expressed "high conviction" that the compa...
Marinus Pharmaceuticals provides updates for pivotal epilepsy study. MediciNova reports data from MN-166 trial for peripheral neuropathy. Exact Sciences shoots up on encouraging liquid biopsy data. For further details see: Marinus Epilepsy Study, And Other News: The Good...
Gainers: Genfit (GNFT) +15%, Evogene (EVGN) +13%, Marinus Pharmaceuticals (MRNS) +11%, Endo International (ENDP) +8%, Happiness Biotech Group (HAPP) +7%.Losers: Rite Aid (RAD) -10%, Cellect Biotechnology (APOP) -8%, Kaleido...
Marinus Pharmaceuticals (MRNS) announces that it has satisfied the FDA's questions regarding the protocol of a Phase 3 clinical trial, RAISE, evaluating intravenous ((IV)) ganaxolone in patients with an extremely severe and life-threatening type of epilepsy called refractory status epilepticu...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...